Burjeel, OncoHelix to bring advanced molecular genetics to UAE

Burjeel, OncoHelix to bring advanced molecular genetics to UAE

UAE - Burjeel Holdings has partnered with OncoHelix to set up a cutting-edge laboratory in Abu Dhabi to provide advanced molecular genetics, cellular and immunological profile testing to patients in the UAE.

Through this exclusive agreement, Burjeel and OncoHelix strive to bring personalised medicine to clinics and hospitals in the UAE.

The agreement was signed by John Sunil, CEO, Burjeel and Dr Faisal Khan, CEO, OncoHelix.

Two areas

The new lab will be divided into two areas. An advanced diagnostic lab arm will focus on offering ground-breaking molecular genetics and immunological profiling tests to assist oncologists and physicians in the diagnosis, risk stratification, and tailored treatment for patients with cancer, genetic diseases, or immune disorders. The second arm will expand on Burjeel’s existing translational research program and analyse cancer patients’ genomic and immune signatures to develop innovative approaches for diagnosis and treatment.

Burjeel expects to commence the operation of the new laboratory by the end of this year, and it will be capable of facilitating the requirements of the region's hospitals.

OncoHelix, based in Western Canada, has the largest breadth of clinically validated comprehensive genomic profiling (CGP) panels for cancer in the country. As part of its academic roles at the University of Calgary, OncoHelix’s scientists